Emerging 2026 Research Is Pointing to a New Root Cause of High Lp(a) — and What Can Finally Be Done About It
I've been treating families who bury a parent at 50 with normal cholesterol for twenty years. For most of those twenty years, the field didn't have a clear answer for why it kept happening.
That's changed.
Over the last several years, a body of research has been building across cardiology, genetics, and blood-clotting journals — and in 2026, what was once a fringe hypothesis is becoming the broadly accepted explanation: the heart attack that runs in your family is, at its core, a condition of blood that can't clear its own clots.
You don't need to take my word for it. Open a new tab and type "lp(a) and blood clots" into Google. Look at what comes up.
Medical journals. Research universities. Clinical reviews. This isn't fringe. It's where the science has landed.
Here's what that actually means.
What Plasminogen Is
Right in your bloodstream, there's a living clean-up enzyme called plasminogen. Think of it as a ring of master keys, but alive, and carried through every artery, every vein, and every tiny vessel in your body, unlocking every clot before it can grow.
When you're young and your blood is healthy, it's switched on and clearing within minutes. Your blood rushes past every scrape without a clot sticking. You don't feel it. It does its job invisibly.
But plasminogen needs the lock on every clot to itself to stay that way — the binding spots it uses to grab the fibrin, switch itself on, and eat the clot away before it hardens.
As you age, that clean-up slows down. Your body produces less of the real key. Inherited Lp(a), stress, and accumulated wear speed the process up — Lp(a) is a dead copy of plasminogen that sits in the lock. The clot stops getting cleared.
So it jams up.
A jammed clot-cleaner loses its fast, self-cleaning quality. It sticks. It stalls. And as it stalls, it begins to physically leave behind everything it should dissolve — including the fibrin piling up inside the arteries that feed your heart.
And once you understand that mechanism, every symptom you've been carrying makes sense.
The number diet never moved
Lp(a) rides in your blood from head to toe. When it jams the clot-cleaner across that many arteries at once, you can eat clean and run for three years with no change — because the entire system was set the day you were born.
The "normal" panel that missed it
Lp(a) hides inside the cholesterol particles your yearly panel counts. When it's high, your sheet still reads normal.
The heart attack out of nowhere
When Lp(a) jams the clot-cleaner in the arteries around your heart, those arteries turn clot-prone. Your dad dropped at 52 with good numbers because the clot was being built long before a single warning ever reached him.
Wondering if you passed it on
When the lock is jammed, every clot lasts longer than it should. By dinner, you're watching your son and wondering if you handed it to him — not because you're paranoid, but because your blood has been fighting a dead key from the inside.
The Research Behind It
This isn't a single study or a fringe theory. It's a converging body of work across multiple labs and journals:
The particle behind high Lp(a) carries a protein that is a near-perfect copy of plasminogen, your blood's own clot-dissolver.
Lp(a) blocks plasminogen from binding where it works — shutting down clot-breaking and pushing the blood toward clots.
In over 40,000 Danes, Lp(a) set by inherited genes drove more heart attacks — 2.6 times the risk at the top.
10,800 FU of nattokinase daily for a year shrank artery plaque and artery-wall thickness in 1,062 people.
These are a few papers out of dozens. All peer-reviewed, all in PubMed, all published in major medical journals.
The 2022 study is the most recent — and it confirms, in 1,062 people, that nattokinase clears the plaque a jammed clot-cleaner leaves behind.
The findings are public. They've just been slow to reach clinical practice.
Why Nothing You've Tried Has Worked
Statins, oatmeal, a lifetime of cardio — everything you've been told to do about the heart disease in your family is designed to do the same thing: lower an LDL your genes never cared about.
None of them touch the reason your blood is clotting in the first place. The Lp(a) is still there, still jamming every clot-cleaner it touches, still leaving behind the clots your statin was never built to see.
That's why the dread never lifts. Nothing in your medicine cabinet was ever pointed at the jammed lock.
What Getting Past The Jammed Lock Actually Requires
It's the same mechanism, in reverse.
Your clots stopped clearing because Lp(a) locked your own enzyme out. Give your blood an enzyme that doesn't need that lock, and the fibrin dissolves. As it dissolves, the artery opens. As it opens, it releases its grip on the blood that feeds your heart — and the clots, the dread, and the family countdown start to resolve at the source.
There's no shortcut around this. You can't drop your LDL low enough, or run far enough, to fix a problem that lives inside your genes. The clot has to be cleared through a different door, with an enzyme Lp(a) can't block.
I spent years recommending the closest things I could find — niacin, fish oil, low-dose nattokinase capsules. I kept coming back to the same conclusion: the ingredients existed, but nothing was putting them together correctly.
So in early 2025, I decided to build the formulation myself.
I teamed up with a small group of lipid and blood-clotting researchers, and we spent the better part of a year working through the literature, sourcing the right forms of each ingredient, and testing the formulation. By the end of 2025, we had it.
Noverly Nattokinase
The formulation centers on three core actives — chosen because they're each in the form that actually reaches the clot.
They're supported by bromelain, turmeric, aged garlic, pine bark, grape seed, and dandelion root — a matrix that helps the actives absorb and reach the clot.
Every ingredient is research-backed. Every dose is based on what the peer-reviewed literature supports. Nothing is in there for marketing — no under-dosed enzyme, no fillers, no ingredients that look impressive on a label but don't reach the clot.
What Happened With The First 1,000 Customers
In early 2026 we ran an initial launch and tracked outcomes from our first 1,000 customers across the first 90 days on the protocol. Among those who completed the full 90 days:
These aren't clinical trial numbers. They're self-reported outcomes from real customers — most of whom had buried a parent young to heart disease and had already tried everything else.
Most reported the shift starting between week three and week six. By day 90, the majority were describing it the same way: not a gene they had outrun, but blood that could finally clean up after itself.
If you've been carrying your family's hidden number long enough to know that lowering your LDL isn't the same as clearing what Lp(a) leaves behind, Noverly is built for what you've actually been looking for.
Try it for 90 days.
If it doesn't work for you in that window, send it back. Full refund. No questions, no fine print, no return process designed to wear you down. I don't want patients paying for something that isn't helping them.